Drug Shortage Report for MOUNJARO
Report ID | 249489 |
Drug Identification Number | 02541076 |
Brand name | MOUNJARO |
Common or Proper name | tirzepatide injection |
Company Name | ELI LILLY CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | TIRZEPATIDE |
Strength(s) | 7.5MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS |
Packaging size | 3 mL single-dose vial |
ATC code | A10BX |
ATC description | |
Reason for shortage | Other (Please describe in comments) |
Anticipated start date | 2025-02-25 |
Actual start date | |
Estimated end date | Unknown |
Actual end date | |
Shortage status | Anticipated shortage |
Updated date | 2025-02-03 |
Company comments | Due to an increase in demand and limited inventory of Mounjaro 7.5 mg vials. All doses of KwikPen 2.5 mg to 12.5 mg are available and KwikPen supply will be prioritized moving forward. For any questions, please contact our Lilly Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v2 | 2025-02-03 | French | Compare |
v1 | 2025-02-03 | English | Compare |
Showing 1 to 2 of 2